What's in Ingrid Pabinger, MD's pipeline?

Ingrid Pabinger, MD has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ingrid Pabinger, MD's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Astellas Pharma Inc, Benazir Bhutto Hospital, Rawalpindi, Berinstein, Jeffrey, Celgene.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ingrid-pabinger-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Ingrid Pabinger, MD — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ingrid Pabinger, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
corticosteroids (Aprednislon)	corticosteroids (Aprednislon)	marketed	Corticosteroid (glucocorticoid)	Glucocorticoid receptor (GR)	Immunology / Rheumatology / General anti-inflammatory

Therapeutic area mix

Immunology / Rheumatology / General anti-inflammatory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class
Benazir Bhutto Hospital, Rawalpindi · 1 shared drug class
Berinstein, Jeffrey · 1 shared drug class
Celgene · 1 shared drug class
Children's Hospital of Philadelphia · 1 shared drug class
Chong Kun Dang Pharmaceutical · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ingrid Pabinger, MD:

Cite this brief

Drug Landscape (2026). Ingrid Pabinger, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ingrid-pabinger-md. Accessed 2026-06-10.